{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:20:59Z","timestamp":1785900059782,"version":"3.56.0"},"reference-count":59,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Primary immune thrombocytopenia (ITP) is an acquired blood disorder that causes a reduction in circulating platelets with the potential for bleeding. The incidence of ITP is slightly higher in adults and affects more women than men until 60 years, when males are more affected. Despite advances in basic science, primary ITP remains a diagnosis of exclusion. The disease is heterogeneous in its clinical behavior and response to treatment. This reflects the complex underlying pathophysiology, which remains ill-understood. Platelet destruction plays a role in thrombocytopenia, but underproduction is also a major contributing factor. Active ITP is a proinflammatory autoimmune disease involving abnormalities within the T and B regulatory cell compartments, along with several other immunological abnormalities. Over the last several years, there has been a shift from using immunosuppressive therapies for ITP towards approved treatments, such as thrombopoietin receptor agonists. The recent COVID-19 pandemic has hastened this management shift, with thrombopoietin receptor agonists becoming the predominant second-line treatment. A greater understanding of the underlying mechanisms has led to the development of several targeted therapies, some of which have been approved, with others still undergoing clinical development. Here we outline our view of the disease, including our opinion about the major diagnostic and therapeutic challenges. We also discuss our management of adult ITP and our placement of the various available therapies.<\/jats:p>","DOI":"10.3390\/medicina59040815","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T04:01:23Z","timestamp":1682308883000},"page":"815","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-2554","authenticated-orcid":false,"given":"Tom\u00e1s Jos\u00e9","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newland","sequence":"additional","affiliation":[{"name":"Academic Haematology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2BB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Provan","sequence":"additional","affiliation":[{"name":"Academic Haematology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2BB, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.hoc.2013.03.001","article-title":"Immune thrombocytopenia","volume":"27","author":"Kistangari","year":"2013","journal-title":"Hematol.\/Oncol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding complications in immune thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.autrev.2017.04.012","article-title":"Pathogenesis of immune thrombocytopenia","volume":"16","author":"Audia","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.hoc.2009.09.003","article-title":"The immune thrombocytopenia syndrome: A disorder of diverse pathogenesis and clinical presentation","volume":"23","author":"Cines","year":"2009","journal-title":"Hematol.\/Oncol. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","article-title":"The incidence of idiopathic thrombocytopenic purpura in adults increases with age","volume":"94","author":"Frederiksen","year":"1999","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"103820","DOI":"10.1016\/j.ebiom.2022.103820","article-title":"Recent advances in the mechanisms and treatment of immune thrombocytopenia","volume":"76","author":"Provan","year":"2022","journal-title":"eBioMedicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2020001654","article-title":"Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia","volume":"4","author":"Comont","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/asheducation-2018.1.561","article-title":"How do we diagnose immune thrombocytopenia in 2018?","volume":"2018","author":"Kelton","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/01.HS9.0000849444.77142.db","article-title":"Contribution of Next Generation Flow (NGF) Cytometry in Primary Immune Thrombocytopenia (ITP): Utility for the Differential Diagnosis with Myelodysplastic Syndromes","volume":"6","author":"Matarraz","year":"2022","journal-title":"HemaSphere"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjh.15404","article-title":"Detection of platelet autoantibodies to identify immune thrombocytopenia: State of the art","volume":"182","author":"Porcelijn","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MOH.0b013e3283567541","article-title":"The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage","volume":"19","author":"Semple","year":"2012","journal-title":"Curr. Opin. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.seminhematol.2010.01.010","article-title":"Rituximab in autoimmune hematologic diseases: Not just a matter of B cells","volume":"47","author":"Stasi","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zufferey, A., Kapur, R., and Semple, J.W. (2017). Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J. Clin. Med., 6.","DOI":"10.3390\/jcm6020016"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood.V100.5.1774.h81702001774_1774_1779","article-title":"Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: Their role in prognosis","volume":"100","author":"Mouzaki","year":"2002","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/bloodadvances.2021006864","article-title":"Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia","volume":"7","author":"Broome","year":"2023","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2009.07995.x","article-title":"Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura","volume":"148","author":"Peerschke","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjh.13648","article-title":"Classical complement pathway activation in immune thrombocytopenia purpura: Inhibition by a novel C1s inhibitor","volume":"173","author":"Peerschke","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jb\/mvp001","article-title":"Protein tyrosine kinase, syk: A key player in phagocytic cells","volume":"145","author":"Tohyama","year":"2009","journal-title":"J. Biochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_24","first-page":"1","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"38","author":"Harrington","year":"1951","journal-title":"J. Lab. Clin. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.lpm.2014.02.006","article-title":"Novel treatments for immune thrombocytopenia","volume":"43","author":"Shih","year":"2014","journal-title":"La Presse M\u00e9dicale"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3389\/fimmu.2018.00880","article-title":"Emerging Concepts in Immune Thrombocytopenia","volume":"9","author":"Swinkels","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1007\/s12325-022-02133-1","article-title":"Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP)","volume":"39","author":"Provan","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1080\/13543784.2022.2075340","article-title":"Investigational drugs for immune thrombocytopenia","volume":"31","author":"Provan","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune Thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2016.161968","article-title":"Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia","volume":"102","author":"Cines","year":"2017","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: Final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjh.17334","article-title":"Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: Results of a phase II, multicentre, prospective study","volume":"193","author":"Lucchini","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/bjh.13266","article-title":"Use of eltrombopag after romiplostim in primary immune thrombocytopenia","volume":"169","author":"Andrade","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study","volume":"197","author":"Jiang","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_37","unstructured":"GEPTI Board of Directors (2023, March 01). Recommendation for the Management of Patients with Immune Thrombocytopenia in the Current Situation of the COVID-19 Pandemic. Available online: https:\/\/www.gepti.es."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00277-021-04662-1","article-title":"Impact of rituximab on COVID-19 outcomes","volume":"100","author":"Levavi","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.medcli.2021.03.017","article-title":"Grupo Espa\u00f1ol de PTI (GEPTI) guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia","volume":"157","author":"Lozano","year":"2021","journal-title":"Med. Clin."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1076029615622002","article-title":"The Effect of Danazol in Primary Immune Thrombocytopenia: An Analysis of a Large Cohort From a Single Center in China","volume":"22","author":"Liu","year":"2016","journal-title":"Clin. Appl. Thromb.\/Hemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: A systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ajh.22266","article-title":"Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab","volume":"87","author":"Zaja","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2014-01-549360","article-title":"Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults","volume":"123","year":"2014","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/ajh.25989","article-title":"High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial","volume":"95","author":"Yu","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2010-04-281717","article-title":"Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents","volume":"116","author":"Bao","year":"2010","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood-2016-01-690727","article-title":"Thrombopoietin receptor agonists shift the balance of Fc\u03b3 receptors toward inhibitory receptor IIb on monocytes in ITP","volume":"128","author":"Liu","year":"2016","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/j.seminhematol.2016.04.010","article-title":"Thrombopoietin receptor agonists: A new immune modulatory strategy in immune thrombocytopenia?","volume":"53","author":"Schifferli","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"100811","DOI":"10.1016\/j.blre.2021.100811","article-title":"Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia","volume":"49","author":"Kuter","year":"2021","journal-title":"Blood Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"T\u0103rniceriu, C.C., Hurjui, L.L., Florea, I.D., Hurjui, I., Gradinaru, I., Tanase, D.M., Delianu, C., Haisan, A., and Lozneanu, L. (2022). Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms. Medicina, 58.","DOI":"10.3390\/medicina58020211"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","article-title":"Revealing eltrombopag\u2019s promotion of human megakaryopoiesis through AKT\/ERK-dependent pathway activation","volume":"101","author":"Currao","year":"2016","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40264-015-0337-1","article-title":"Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase\u00ae","volume":"38","author":"Nguyen","year":"2015","journal-title":"Drug Saf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2131751","DOI":"10.1080\/09537104.2022.2131751","article-title":"Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib","volume":"34","author":"Cooper","year":"2023","journal-title":"Platelets"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000520438","article-title":"Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk","volume":"145","author":"Mehta","year":"2022","journal-title":"Acta Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406207211010875","article-title":"Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib","volume":"12","author":"Cooper","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ejim.2014.09.006","article-title":"Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009\u20132013 French PharmacoVigilance assessment","volume":"25","author":"Moulis","year":"2014","journal-title":"Eur. J. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.26378","article-title":"Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietinreceptor agonists: New insights for an old treatment","volume":"97","author":"Mageau","year":"2022","journal-title":"Am. J. Hematol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/4\/815\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:21:02Z","timestamp":1760124062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/4\/815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["medicina59040815"],"URL":"https:\/\/doi.org\/10.3390\/medicina59040815","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]}}}